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Aim. MI1 is a promising maleimide derivative, which exhibits antiproliferative effect on different cells. The aim
of present study was to investigate influence of MI1 on the cell cycle of cancer cells and its cytotoxity.Methods.
The proliferative activity and viability of human cancer cell lines (colorectal adenocarcinoma – Colo-205;
breast cancer – MCF-7; cervix cancer HeLa) obtained with MTT-test and cell counts were performed using a
tripan blue dye. Distribution of cell cycle phases was obtained using flow cytometry method. Results. In the
present study we demonstrate a detectable cytostatic effect of the maleimide derivative MI1 on the epithelial cell
lines Colo-205, MCF-7 and HeLa. In the presence of MI1 the number of cells in the G
2
/M+S phases of the cell
cycle dropped by 20–30 % (p < 0.05) relative to control. Conclusions. The results suggest that MI1 may be a
perspective drug for antitumor therapy and perhaps deserves further study in detail.
Keywords: maleimide derivatives, cell cycle, cell culture.
Introduction. Protein kinase hyperactivity is often ob-
served in different types of tumor cells. This activity
permanently stimulates proliferative signal cascades,
increasing the frequency of cells entering the mitotic
phase, which is one of the major features of malignan-
cy. Protein kinase inhibition can promote cell cycle ar-
rest [1–4], thus preventing malignization.
Some characteristics of the chemical structure of ma-
leimide make it a perspective cytostatic agent. By the end
of the ÕÕ century, a number of maleimide derivates,
such as bisindolylmaleimides, azoindolylmaleimides,
and arylindolylmaleimide, were known for their anti-
proliferative effects [5]. The antiproliferative effects on
cancer cells are produced by the products of nucleo-
philic substitution of a chlorine atom in the 3,4-dichlo-
ro-1H-pyrrole-2,5-dione (maleimides) with N-nucleo-
philes (primary, secondary aliphatic, and aromatic ami-
nes). The set of maleimide derivatives for our study
was synthesized at Research and Production Bioche-
mical Center of Taras Shevchenko National University
after the stage of in silico design.
The general scheme of the synthesis is shown in Fig.
1. As revealed by the results of pre-screening, the sub-
stance number 1.14 turned out to be the most potent cy-
tostatic one, with the lowest general toxicity. This agent
was classified as 1-(4-Cl-benzyl)-3-Cl-4-(CF3-phenyl-
amino)-1H-pirrol-2,5-dion, hereby denoted asMI1 (Fig.
2) [6]. At the in silico stage of substance molecular
design, we expected that its spatial configuration would
be complementary to the ATP-binding site of protein ki-
nases. MI1 conformation resembles the ATP molecule
but lacks the sites of hydrolysis and can act as a competi-
tive inhibitor of protein kinases. The biochemical stu-
dies showed its ability to inhibit enzymes of protein ki-
nase class, especially effective against tyrosine kinases
[6, 7]. The strong cytostatic and low cytotoxic effects of
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MI1 have been observed in tests on some epithelial deri-
ved cell lines [8]. The animal studies have confirmed a
low toxic influence of MI1 on the digestive tract and re-
productive system [9–11]. Ì²1 significantly suppresses
the development of 1,2-dimethylhydrazine-induced co-
lorectal tumors, both in prevention and in the treatment
modes [12].
Therefore, the promising findings from previous
studies suggest that MI1 should be explored more tho-
roughly. The aim of the present research was to investi-
gate the effect of MI1 on the cell cycle progression, pro-
liferative activity, and viability of transformed epithe-
lium derived cells.
Materials andmethods. Human epithelial derived
cell lines were used to determine the cytotoxic/cyto-
staticMI1 effects. These were the colorectal cancer cell
line Colo-205, the breast cancer line MCF-7, and the
cervix cancer line HeLa (cell lines were kindly provi-
ded by Dr I. Goot, University of London).
Cells were incubated with MI1 for 24 h under nor-
mal conditions in 96 well plates for MTT-test. Initial
cell concentration was about 5 10
4 cells/ml in the samp-
le volume of 100 µl. As a culture media, we used DMEM
(«Sigma», USA) with 10 % FBS («Sigma»), 2 mM L-
glutamine, and 40 µg/ml gentamicin. Different concen-
trations of MI1 were added to cell cultures in 100 µl of
media after the period of cell adaptation in normal con-
ditions (5 % CO2, 100 humidity, 37
oC) during 4 h. The
number of living cells was determined in wells using
MTT-colorymetric test and cell counts were performed
using a tripan blue dye after 24 h incubation with MI1
[13]. TheMI1 cytotoxic effect was evaluated as percent
of live cells relative to control and characterized by IC50
index.
The distribution of cells in different phases of the cell
cycle was assessed by flow cytometry [14]. Cells were
plated in 6-well plates at the density 5  10
4 cells/ml in
total volume 5 ml of complete culture medium. Cells
were incubated with MI1 at densities ten times lower
than the IC50 index estimated for each line by MTT-test.
The cells were incubated for 48 h under normal condi-
tions. The proportions of cells in different phases of the
cell cycle were measured by flow cytometry with argon
laser (excitation = 488 µm,emission = 585/40 µm) («Becton
Dickinson», USA) following standard staining. The
samples were analyzed with the help of the Mod Fit LT
3.0 («BDIS», USA) software.
Results and disscusion. The results of cytostatic/cy-
totoxic screening showed that themost susceptible toMI1
cell line was MCF-7. The IC50 index for MCF-7 was
0.21 mM (Fig. 3, B), while for HeLa and Colo-205 the
indiceswere 0.43 and 0.63mM, respectively (Fig. 3,À,C).
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Fig. 1. General synthesis
pathway of 1-(4-R-ben-
zyl)-3-cloro-4-(R2-penyl-
amino)-2,5-dyhidro-1N-
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Fig. 2. Substance 1.14: 1-(4-Cl-benzyl)-3-Cl-4-(CF
3
-phenylamino)-
1H-pirrol-2,5-dion (MI1)
Our results confirm earlier evidence indicating low
cytotoxity of MI1 for cell cultures and reveal its anti-
proliferative effect. For that reason each cell line was in-
cubated at corresponding MI1 concentration that was
ten times lower than the IC50 index. The concentrations
used were as follows: for HeLa – 0.04 mM, for MCF-7 –
0.02 mM, and for Colo-205 – 0.06 mM. The ratio of
live to dead cells was calculated in hemocytometer with
trypan blue staining. The Colo-205 cell line was the
most susceptible to MI1 toxic influence and demons-
trated 17 ± 1.5 % dead cells (Table), while HeLa and
MCF-7 cells showed higher survival rates (more than
90 %) relative to control.
Thus, only Colo-205 cells demonstrated enchanced
susceptibility to toxic effect at subtoxic Ì²1 concen-
trations.
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Fig. 3. Results of cytostatic/cytotoxic screening ofMI1 effect for HeLa (A, IC
50
= 0.43mM),MCF-7 (B, IC
50
= 0.21mM), Colo-205 (C, IC
50
= 0.63 mM):
MTT-test (a) and flow cytometry (b) data demonstrate cell cycle suppression (b: 1 – control; 2 – MI1)
The pool of proliferating cells decreased in all the
lines tested (Fig. 3). The proportion of total cell popu-
lation in G2/M + S phases for Hela was 45.6 ± 2.5 % in
control and 35.4 ± 0.6 %with MI1; for MCF-7 – 52.4 ±
± 0.7 % in control and 39.4 ± 0.7 % in the test; for
Colo-205 it was – 56.7 ± 0.9 % and 45.4 ± 0.8 %,
respectively. The fraction of cell population in G1/G0
phases increased, thus, revealing a clear cytostatic effect
of the tested substance. The described MI1cytostatic ef-
fects were probably based on the previously observed
tyrosine kinase inhibitory activity.
Conclusions. 1. 1-(4-Cl-benzyl)-3-Cl-4-(CF3-phe-
nylamino)-1H-pirrol-2,5-dion is demonstrates a mode-
rate toxic effect on epithelial derived tumor cells. IC50
index is: for HeLa – 0.43 mM, for MCF-7 – 0.21 mM,
for Colo-205 – 0.63 mM.
2. Cell survival at subtoxic concentrations Ì²1
(IC50) did not significantly differ from control for HeLa
and MCF-7, and was lower for Colo-205 (82.8 ± 5.4 %
versus 93.6 ± 0.9 %).
3. Flow cytometry analysis demonstrated that in the
presence of MI1 cells tend to enter the G1/G0 phase.
The proportion of non-dividing cells increased by 20–
30 % (p < 0.05).
Ë. Â. Ãàðìàí÷óê, ª. Î. Äåí³ñ, Â. Â. Í³êóë³íà, Î. ². Äæóñ,
Î. Â.Ñêà÷êîâà, Â. Ê. Ðèáàëü÷åíêî, Ë. ².Îñòàï÷åíêî
M²1 – ïîõ³äíå ìàëå¿ì³äó ïðèãí³÷óº ïðîãðåñ³þ êë³òèííîãî öèêëó
ó ïóõëèííèõ êë³òèíàõ åï³òåë³àëüíîãî ïîõîäæåííÿ
Ðåçþìå
Ìåòà. Äëÿ ïîõ³äíîãî ìàëå¿ì³äó M²1 âèÿâëåíî ïðèãí³÷åííÿ ïðîë³ôå-
ðàö³¿ êë³òèí, îïîñåðåäêîâàíå ³íã³áóâàííÿì òèðîçèíê³íàç. Ìåòà äà-
íî¿ ðîáîòè ïîëÿãàëà â ïîãëèáëåíîìó âèâ÷åíí³ âïëèâó M²1 íà ïåðå-
á³ã êë³òèííîãî öèêëó ó ïóõëèííõ êë³òèíàõ, à òàêîæ íà ¿õíþ æèò-
òºçäàòí³ñòü.Ìåòîäè. Ïðîë³ôåðàòèâíó àêòèâí³ñòü òàæèòòº-
çäàòí³ñòü êë³òèííèõ ë³í³é ðàêó ëþäèíè (êîëîðåêòàëüíà àäåíî-
êàðöèíîìà – Colo-205; ðàê ìîëî÷íî¿ çàëîçè – MCF-7; ðàê øèéêè
ìàòêè HeLa) âèçíà÷àëè çà äîïîìîãîþ ÌÒÒ-òåñòó òà ðóòèííîãî
ï³äðàõóíêó êë³òèí, çàáàðâëåíèõ òðèïàíîâèì ñèí³ì. Ðîçïîä³ë êë³-
òèííî¿ ïîïóëÿö³¿ çà ôàçàìè êë³òèííîãî öèêëó çä³éñíþâàëè ìåòî-
äîì ïðîòî÷íî¿ öèòîôëóîðèìåòð³¿. Ðåçóëüòàòè. Ïîêàçàíî öèòî-
ñòàòè÷íó ä³þ ïîõ³äíîãî ìàëå¿ì³äó M²1 ùîäî êë³òèííèõ ë³í³é åï³-
òåë³àëüíîãî ïîõîäæåííÿ Colo-205, MCF-7 ³ HeLa. Òàê, ê³ëüê³ñòü
êë³òèí ó ôàçàõ G2/M + S êë³òèííîãî öèêëó çìåíøóâàëàñÿ ïðèáëèç-
íî ó 1,2–1,3 ðàçó (p < 0.05) äëÿ âñ³õ êë³òèííèõ ë³í³é çà âïëèâó ìà-
ëå¿ì³äó ïîð³âíÿíî ç êîíòðîëåì. Âèñíîâêè. M²1 ìîæíà ðîçãëÿäà-
òè ÿê ïåðñïåêòèâíó ïðîòèïóõëèííó ñïîëóêó, ùî ïîòðåáóº ïîäàëü-
øîãî äîñë³äæåííÿ.
Êëþ÷îâ³ ñëîâà: ïîõ³äí³ ìàëå¿ì³äó, êë³òèííèé öèêë, êë³òèíí³
êóëüòóðè.
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Î. Â.Ñêà÷êîâà, Â. Ê. Ðûáàëü÷åíêî, Ë. È.Îñòàï÷åíêî
M²1 – ïðîèçâîäíîå ìàëåèìèäà ïîäàâëÿåò ïðîãðåññèþ êëåòî÷íîãî
öèêëà â îïóõîëåâûõ êëåòêàõ ýïèòåëèàëüíîãî ïðîèñõîæäåíèÿ
Ðåçþìå
Öåëü. Äëÿ ïðîèçâîäíîãî ìàëåèìèäà M²1 îáíàðóæåíî çàìåäëåíèå
ïðîëèôåðàöèè êëåòîê, îïîñðåäîâàííîå èíãèáèðîâàíèåì òèðîçèí-
êèíàç. Öåëü äàííîé ðàáîòû ñîñòîÿëà â óãëóáëåííîì èçó÷åíèè âëè-
ÿíèÿ M²1 íà ïðîõîæäåíèå êëåòî÷íîãî öèêëà â ðàêîâûõ êëåòêàõ, à
òàêæå íà èõ âûæèâàåìîñòü. Ìåòîäû. Ïðîëèôåðàòèâíóþ àê-
òèâíîñòü è âûæèâàåìîñòü êëåòî÷íûõ ëèíèé ðàêà ÷åëîâåêà (êî-
ëîðåêòàëüíàÿ àäåíîêàðöèíîìà – Colo-205; ðàê ìîëî÷íîé æåëå-
çû – MCF-7; ðàê øåéêè ìàòêè – HeLa) îïðåäåëÿëè ñ ïîìîùüþ
ÌÒÒ-òåñòà è ðóòèííîãî ïîäñ÷åòà êëåòîê, îêðàøåííûõ òðèïàíî-
âûì ñèíèì. Ðàñïðåäåëåíèå êëåòî÷íîé ïîïóëÿöèè ïî ôàçàì êëåòî÷-
íîãî öèêëà ïðîèçâîäèëè ìåòîäîì ïðîòî÷íîé öèòîôëóîðèìåò-
ðèè. Ðåçóëüòàòû. Ïîêàçàíî öèòîñòàòè÷åñêîå è àíòèïðîëèôå-
ðàòèâíîå äåéñòâèå ïðîèçâîäíîãî ìàëåèìèäà M²1 íà êëåòî÷íûå
ëèíèè ýïèòåëèàëüíîãî ïðîèñõîæäåíèÿ Colo-205, MCF-7 è HeLa.
Òàê, êîëè÷åñòâî êëåòîê â ôàçàõ G2/M + S êëåòî÷íîãî öèêëà óìåíü-
øàëîñü â 1,2–1,3 ðàçà (p < 0.05) äëÿ âñåõ ëèíèé ïî ñðàâíåíèþ ñ êîíò-
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Cells
Cells, %
HeLa MCF-7 Colo-205
Control
live 92.9 ± 3.2 94.5 ± 3.9 93.6 ± 0.9
dead 8.5 ± 2.5 6.9 ± 3.2 5.8 ± 3.2
Concentration of Ì²1, mM
0.04 0.02 0.06
live 89.5 ± 2.5 90.2 ± 3.7 82.8 ± 5.4
dead 12.6 ± 3.8 11.4 ± 1.9 17 ± 1.5*
*p < 0.05, against control.
Cells viability under the MI1 influence (cell counts were performed using a tripan blue dye)
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ðîëåì. Âûâîäû. Ïðîèçâîäíîå ìàëåèìèäà M²1 ìîæíî ðàññìàòðè-
âàòü êàê ïåðñïåêòèâíîå ïðîòèâîîïóõîëåâîå ñîåäèíåíèå, ÷òî òðå-
áóåò äàëüíåéøèõ èññëåäîâàíèé.
Êëþ÷åâûå ñëîâà: ïðîèçâîäíûå ìàëåèìèäà, êëåòî÷íûé öèêë,
êëåòî÷íûå êóëüòóðû.
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